Can BCR inhibitors be used to treat all CLL patients or only a subset?

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz, MD, PhD, from H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the use of B-cell receptor (BCR) inhibitors, namely PI3K inhibitors and BTK inhibitors, in treating chronic lymphocytic leukemia (CLL) and their differing effects in different subsets of patients, which presents a concern. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video